|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Jerzy Muchnicki||Interim CEO & Exec. Director||N/D||N/D||1957|
|Dr. Richard Allman||Scientific Director||N/D||N/D||1960|
|Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI||Consultant||N/D||N/D||N/D|
|Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA||Chief Financial Officer||N/D||N/D||1961|
|Mr. Stanley Sack||Chief Operating Officer||N/D||N/D||1964|
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company also engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. In addition, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
L'ISS Governance QualityScore di Genetic Technologies Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.